UNSPSC 51401545: Proflazepam

This classification denotes a benzodiazepine with the molecular formula C18H16ClFN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 545MN0F125, chemically known as 7-chloro-1-(2,3-dihydroxypropyl)-5-(o-fluorophenyl)-1,3-dihydro-2h-1,4-benzodiazepin-2-one but generally known as proflazepam, which bears US NIH Compound Identifier 3050433. European Medicines Agency schedules Proflazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10074MIG.

UNSPSC 51401545 Proflazepam is a Commodity-tier code that shows little alignment with the recent state and local procurement activity tagged to it. The three most recent opportunities—naloxone and drug-deactivation systems procurement (Seminole County, Florida), a direct-to-manufacturer pharmacy initiative RFI (Texas Health and Human Services Commission), and a multistate generic pharmaceuticals cooperative contract (Minnesota MMCAP)—involve naloxone, pharmacy benefit management, and over-the-counter products respectively, none of which are proflazepam or benzodiazepine-class pharmaceutical procurement. The mismatch suggests either miscategorization by the issuing bodies or that proflazepam procurement through state and local governments is not currently active in the tracked opportunity set.

Without recent opportunities directly soliciting proflazepam supply, no reliable characterization of issuing-body concentration, geographic spread, or active demand under this code is possible. A business development professional evaluating this code should verify whether state and local governments actually procure proflazepam through formal channels, or whether procurement activity—if any exists—falls under broader pharmaceutical or health-system contracts that use higher-tier family or segment codes instead. The recent activity tagged to this code does not support a pursue decision based on current market signals.